Clinical trials
Completed Phase 2 Idiopathic Pulmonary Fibrosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
65 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 5 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 9 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 65 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boehringer Ingelheim | 4 |
| Hoffmann-La Roche | 4 |
| Pliant Therapeutics, Inc. | 3 |
| Actelion | 2 |
| Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2 |
| Biogen | 2 |
| Bristol-Myers Squibb | 2 |
| InterMune | 2 |
| Kyntra Bio | 2 |
| Lakefront Biotherapeutics NV | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Idiopathic Pulmonary Fibrosis | 65 |
| Pulmonary Fibrosis | 14 |
| Lung Diseases, Interstitial | 6 |
| Cough | 5 |
| Hypertension, Pulmonary | 4 |
| Idiopathic Interstitial Pneumonias | 4 |
| Lung Diseases | 4 |
| Pulmonary Arterial Hypertension | 4 |
| Fibrosis | 3 |
| Respiratory Tract Diseases | 3 |
Trials
Showing 1 to 25 of 65. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.